title: Diagnosing and treating neurogenic orthostatic hypotension in primary care.
abstract: In response to a change in posture from supine or sitting to standing, autonomic reflexes normally maintain blood pressure (BP) by selective increases in arteriovenous resistance and by increased cardiac output, ensuring continued perfusion of the central nervous system. In neurogenic orthostatic hypotension (NOH), inadequate vasoconstriction and cardiac output cause BP to drop excessively, resulting in inadequate perfusion, with predictable symptoms such as dizziness, lightheadedness and falls. The condition may represent a central failure of baroreceptor signals to modulate cardiovascular function, a peripheral failure of norepinephrine release from cardiovascular sympathetic nerve endings, or both. Symptomatic patients may benefit from both non-pharmacologic and pharmacologic interventions. Among the latter, two pressor agents have been approved by the US Food and Drug Administration: the sympathomimetic prodrug midodrine, approved in 1996 for symptomatic orthostatic hypotension, and the norepinephrine prodrug droxidopa, approved in 2014, which is indicated for the treatment of symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy and pure autonomic failure). A wide variety of off-label options also have been described (e.g. the synthetic mineralocorticoid fludrocortisone). Because pressor agents may promote supine hypertension, NOH management requires monitoring of supine BP and also lifestyle measures to minimize supine BP increases (e.g. head-of-bed elevation). However, NOH has been associated with cognitive impairment and increases a patient's risk of syncope and falls, with the potential for serious consequences. Hence, concerns about supine hypertension - for which the long-term prognosis in patients with NOH is yet to be established - must sometimes be balanced by the need to address a patient's immediate risks.
authors.affiliation: a 1 Department of Community Health and Family Medicine, University of Florida , Gainesville, FL, USA.
authors.forename: Louis
authors.initials: L
authors.lastname: Kuritzky
authors.forename: Alberto J
authors.initials: AJ
authors.lastname: Espay
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Gelblum
authors.forename: Richard
authors.initials: R
authors.lastname: Payne
authors.forename: Eric
authors.initials: E
authors.lastname: Dietrich
mesh_terms: D000058:Accidental Falls / Q000517:prevention & control*; D000368:Aged; D000369:Aged, 80 and over; D001342:Autonomic Nervous System Diseases / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D019468:Disease Management; D015103:Droxidopa / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007024:Hypotension, Orthostatic / Q000175:diagnosis / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D008297:Male; D008879:Midodrine / Q000494:pharmacology*; D014662:Vasoconstrictor Agents / Q000494:pharmacology
chemical_list: D014662:Vasoconstrictor Agents; D008879:Midodrine; D015103:Droxidopa
keywords: Neurogenic orthostatic hypotension; reduction of falls; supine blood pressure; supine hypertension